Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.
Human GLP-1 (glucagon-like peptide-1) can produce a remarkable improvement in glycemic control in patients with type 2 diabetes. However, its clinical benefits are limited by its short half-life, which is less than 2 min because of its small size and rapid enzymatic inactivation by dipeptidyl peptid...
Main Authors: | Yi Yang, Fang Chen, Deyou Wan, Yunhui Liu, Li Yang, Hongru Feng, Xinling Cui, Xin Gao, Haifeng Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4883776?pdf=render |
Similar Items
-
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
by: Qinghua Wang, et al.
Published: (2010-09-01) -
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01) -
A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
by: Noura Al-Zamel, et al.
Published: (2019-07-01) -
GLP-1 Receptor Agonists and Kidney Protection
by: Eulalia Valentina Greco, et al.
Published: (2019-05-01) -
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
by: Xin Zhao, et al.
Published: (2021-08-01)